Concepedia

Kang Cheng

KC

50

Publications

4K

Citations

31

H-Index

1983

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Nanjing Agricultural University

Arena Pharmaceuticals (United States)

Kang Cheng is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and physiology.

ORCID

Top concepts

Publications per year

1983–2024

50

Publications

50

(d)-β-Hydroxybutyrate Inhibits Adipocyte Lipolysis via the Nicotinic Acid Receptor PUMA-G

Andrew K.P. Taggart, Jukka Kero, Xiaodong Gan et al. · Journal of Biological Chemistry · 2005 · 636 citations · Full text

11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice

Anne Hermanowski‐Vosatka, James M. Balkovec, Kang Cheng et al. · The Journal of Experimental Medicine · 2005 · 362 citations · Full text

A Nonpeptidyl Growth Hormone Secretagogue

Roy G. Smith, Kang Cheng, William R. Schoen et al. · Science · 1993 · 348 citations

, , +9

A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocytes.

Shinji Tamura, Thomas A. Brown, Judith H. Whipple et al. · Journal of Biological Chemistry · 1984 · 347 citations · Full text

Role of GPR81 in lactate-mediated reduction of adipose lipolysis

Tian‐Quan Cai, Ning Ren, Lan Jin et al. · Biochemical and Biophysical Research Communications · 2008 · 286 citations

, , +4

Rows per page

1–5 of 50